Protalix generates revenue primarily through commercial product sales, milestone payments, and strategic licensing partnerships with global pharmaceutical entities. Key revenue streams include manufacturing and supplying enzyme replacement therapies—such as Elfabrio in collaboration with Chiesi and Elelyso through Pfizer—alongside regulatory milestone achievements and cooperative research and development fees stemming from its proprietary plant cell expression technology platform.